Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2021Yazar
Cömert Önder, F.Kahraman, N.
Bellur Atıcı, E.
Cagır, A.
Kandemir, Hakan
Tatar, G.
Özpolat, Bülent
Üst veri
Tüm öğe kaydını gösterÖzet
Eukaryotic elongation factor 2 kinase (eEF-2K) is an unusual alpha kinase involved in protein synthesis through phosphorylation of elongation factor 2 (EF2). eEF-2K is highly overexpressed in breast cancer, and its activity is associated with significantly shortened patient survival and proven to be a potential molecular target in breast cancer. The crystal structure of eEF-2K remains unknown, and there is no potent, safe, and effective inhibitor available for clinical applications. We designed and synthesized several generations of potential inhibitors. The effect of the inhibitors at the binding pocket of eEF-2K was analyzed after developing a 3D target model by using a domain of another ?-kinase called myosin heavy-chain kinase A (MHCKA) that closely resembles eEF-2K. In silico studies showed that compounds with a coumarin-chalcone core have high predicted binding affinities for eEF-2K. Using in vitro studies in highly aggressive and invasive (MDA-MB-436, MDA-MB-231, and BT20) and noninvazive (MCF-7) breast cancer cells, we identified a lead compound that was highly effective in inhibiting eEF-2K activity at submicromolar concentrations and at inhibiting cell proliferation by induction of apoptosis with no toxicity in normal breast epithelial cells. In vivo systemic administration of the lead compound encapsulated in single lipid-based liposomal nanoparticles twice a week significantly suppressed growth of MDA-MB-231 tumors in orthotopic breast cancer models in nude mice with no observed toxicity. In conclusion, our study provides a highly potent and in vivo effective novel small-molecule eEF-2K inhibitor that may be used as a molecularly targeted therapy breast cancer or other eEF-2K-dependent tumors. © 2021 American Chemical Society.
Cilt
4Sayı
2Koleksiyonlar
İlgili Öğeler
Başlık, yazar, küratör ve konuya göre gösterilen ilgili öğeler.
-
The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases
Urvay, Semiha; Eren, Tülay; Civelek, Burak; Kılıçkap, Sadettin; Yetişyiğit, Tarkan; Özaslan, Ersin (Zerbinis Publications, 2020)Purpose: Whether primary tumor resection (PTR) should be performed in patients with asymptomatic colorectal cancer (CRC) and unresectable synchronous metastasis is controversial. The purpose of this study was to investigate ... -
Evaluation of the relationship between serum ghrelin levels and cancer cachexia in patients with locally advanced nonsmall-cell lung cancer treated with chemoradiotherapy
Uysal, Pelin; Usul Afşar, Çiğdem; Sözer, Volkan; İnanç, Berrin; Ağaoğlu, Fulya; Güral, Zeynep; Uzun, Hafize; Fazlıoğlu, Nevin (Wolters Kluwer Medknow Publications, 2020)Background: Ghrelin plays a role in mechanisms related to cancer progression - including cell proliferation, invasion and migration, and resistance to apoptosis in the cell lines from several cancers. We investigated the ... -
PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer
Zengin, Mehmet; Zergeroğlu, Sema; Okcu, Oğuzhan; Benek, Suat (Springer Science and Business Media B.V., 2021)Background: Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were ...